Protective effect of Sijunzi decoction on neuromuscular junction ultrastructure in autoimmune myasthenia gravis rats

Journal of Traditional Chinese Medicine

Volumn 33, Issue 5, 2013, Pages 669-673

  Wu, Haibin ^a   She, Shifeng ^a   Liu, Youzhang ^a   Xiong, Wensheng ^a   Guo, Yalei ^a   Fang, Huansong ^a   Chen, Hong ^a   Li, Jia ^a  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Adenosine triphosphate; Mitochondria; Myasthenia gravis; Neuromuscular junction; Respiratory chain complex; Sijunzi decoction

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHOLINERGIC RECEPTOR; PLANT MEDICINAL PRODUCT; PREDNISONE; SIJUNZI DECOCTION; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ULTRASTRUCTURE; ELECTRON MICROSCOPE; GASTROCNEMIUS MUSCLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MITOCHONDRION; MUSCLE CELL; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; OXYGEN ELECTRODE; RAT; RESPIRATORY CHAIN; TORPEDO; TRANSMISSION ELECTRON MICROSCOPE;

ADENOSINE TRIPHOSPHATE; ANIMALS; DRUGS, CHINESE HERBAL; ELECTRON TRANSPORT COMPLEX I; ELECTRON TRANSPORT COMPLEX II; FEMALE; HUMANS; MITOCHONDRIA; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; PROTECTIVE AGENTS; RATS; RATS, INBRED LEW;

EID: 84887710187     PISSN: 02552922     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0254-6272(14)60040-6     Document Type: Article

References (33)

1. Meriggioli M N, Howard J F, Harper C M. Diagnostic tests for neuromuscular junction disorders. In: Meriggioli MN, Howard JF, Harper CM, eds. Neuromuscular junction disorders: diagnosis and treatment. New York: Informa Healthcare, 2004: 59-95.
2. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscular Disord 2006; 16(7): 459-467.
3. Guyon T, Wakkach A, Poea S, et al. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss. Clin Invest 1998; 102(1): 249-263.
4. Rostedt Punga A, Ahlqvist K, Bartoccioni E, et al. Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol 2006; 117(7): 1434-1443.
5. Shigemoto K, Kubo S, Maruyama N, et al. Induction of myasthenia by immunization against muscle-specific kinase. Clin Invest 2006; 116(4): 1016-1024.
6. Liu Y Z. An exploration of the nature of "spleen" in Traditional Chinese Medicine on a subcellular level: A study on the gastric mucosal ultrastructure of 51 cases. Zhong Yi Wen Zhai 1987; 11(3&4): 34-37.
7. Liu Y Z, Ning G, Ogawa Kazuo. Electron microscopic observation of gastric mucosa in patients who diagnosed as deficiency of spleen-stomach energy in Recent-development of electron microscopy. Proceedings of sixth Chinese-Japanese electron microscopy seminar. 1991 Nov. Okayama, Japan. 1991; 23(2): 155-158.
8. Velltura-Clapier R, Gamier A, Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1 lalpha. Cardiovasc Res 2008; 79(2): 208-217.
9. Mium S, Tomitsuka E, Kaxnei Y, et al. Overexpression of peroxisome proliferator-activated receptor gamma co-activator-lalpha leads to muscle atrophy with depletion of ATP. Am J Pathol 2006; 169(4): 1129-1139.
10. Guidance Suggestions for the Care and Use of Laboratory Animals. The Ministry of Science and Technology of the People's Republic of China, 2006.
11. Schimidt J, Raftery M A. Purification of acetylcholine receptors from Torpedo Californica electroplax by affinity chromatography. Biochemistry 1973; 12(5): 852-856.
12. Christadoss P, Poussin M, Deng C. Animal models of myasthenia gravis. Clin Immunol 2000; 94(2): 75-87.
13. Lennon V A, Lindstrom J M, Seybold M E. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J Exp Med 1975; 141(6): 1365-1375.
14. Sun W, Zhang J S, Liu P, et al. Study on experimental autoimmune myasthenia gravis (EAMG) rat model. Zhong Yi Yao Xue Kan 2005; 23(5): 812-814.
15. Song Y F, Hu R F, Liu Y Z. Cases review and experimental research on interference with musc1e ce11 damage on myasthenia gravis. Zhong Yao Yao Li Yu Lin Chuang 2010; 26(1): 65-68.
16. Kesavulu M M, Rao B K, Giri R, et al. Lipid peroxidation and antioxidant enzyme status in Type 2 diabetics with coronary heart disease. Diabetes Res Clin Pract 2001; 53(1): 33-39.
17. Estabrook R W. Oxidative and phosphorylation methods in enzymology. New York: Academic Press, 1967: 45-51.
18. Im S H, Barchan D, Maiti P K, et al. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J Immunol 2001; 166(11): 6893-6898.
19. Heaton R W, Arnold I R, Howard N, et al. Successful treatment of chylothorax and superior vena cava obstruction by radiotherapy. Clin Immunol 1987; 42(2): 153-156.
20. Ben-David H, Aruna B V, Seger R, et al. A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses. Proc Natl Acad Sci USA 2006; 103(48): 18232-18237.
21. Tuzun E, Saini S S, Morgan B P, et al. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis. J Neuroimmunol 2006; 181(1-2): 29-33.
22. Aruna B V, Sela M, Mozes E. Down-regulation of T cell responses to AchR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4+CD25+ regulatory cells. J Neuroimmunol 2006; 177(1-2): 63-75.
23. Zhu K Y, Feferman T, Maiti P K, et al. Intravenous immunoglobulin suppresses experiment myasthenia gravis: immunological mechanisms. J Neuroimmunol 2006; 176(1-2): 187-197.
24. Bakhiet M, Yu LY, Ozenci V, et al. Modulation of immune responses and suppression of experimental myasthenia gravis by surgical denervation of the spleen. Clin Exp Immunol 2006; 144(2): 290-298.
25. Romi F, Skeie G O, Aarli J A, et al. Muscle autoantibodies in subgroups of myasthenia gravis patients. Neurology 2008; 247(5): 369-375.
26. Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity. Lancet 1986; 327(8473): 116-119.
27. Ciafaloni E, Massey J M, Tucker lipscomb B, et al. Mycophenoate mofetil for myasthenia gravis: an open-able pilot study. Neurology 2001; 56(1): 97-99.
28. Antonio-Santos A A, Eggenberger E R. Medical treatment options for ocular myasthenia gravis. Curr Opin Ophthalmol 2008; 19(6): 468-478.
29. Farrugia M E, Robson M D, Clover L, et al. MRI and clinical studies of facial and bulbar involvement in MuSK antibody-associated myasthenia gravis. Brain 2006; 129(6): 1481-1492.
30. Yang M S, Cao X B. Research advancement in myasthenia gravis. Zhong Guo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi 2010; 9(2): 63-64.
31. Liu Y Z, Wang C J, Zhou J J, et al. Effect and mechanism of Sijunzi decoction in the amelioration of mitochondria's cytochrome oxidase in rats with spleen asthenia. Zhongguo Lin Chuang Kang Fu 2006; 10(35): 118-122.
32. Bloeh R J. Dispersal and reformation of acetylcholine receptor clusters of cultured rat myotubes treated with inhibitors of energy metabolism. Cell Biol 1979; 82(3): 626-643.
33. Finsterer J, Oberman I, Reitner A. Respiratory chain complex-1 defect mimicking myasthenia. Metab Brain Dis 2002; 17(1): 41-46.